EVIDENCE. COMPARISONS. CLEAR NEXT STEPS.FOR US CLINIC TEAMS PROCUREMENT RESEARCH
Readiness quiz

Sources

Dose Diligence research deskSection 08 · Page 22 of 22Last updated 17 Nov 2026

Primary sources below were reviewed for this research. Their publication or update dates differ from this document’s review date. Manufacturer pages establish published programme descriptions and terms, not independently verified service performance.

  1. FDA — GLP-1 compounding policy clarification, including the April 1, 2026 update. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
  2. FDA — Proposed exclusion of semaglutide, tirzepatide and liraglutide from the 503B bulks list, April 30, 2026. https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list
  3. FDA — FD&C Act provisions applying to human drug compounding. https://www.fda.gov/drugs/human-drug-compounding/fdc-act-provisions-apply-human-drug-compounding
  4. California State Board of Pharmacy — Verify a licence. https://www.pharmacy.ca.gov/about/verify_lic
  5. California State Board of Pharmacy — Nonresident sterile compounding pharmacy application. https://www.pharmacy.ca.gov/forms/nrp_comp_app_pkt.pdf
  6. FDA — Registered outsourcing facilities. https://www.fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities
  7. FDA — Form 483 frequently asked questions. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/inspection-references/fda-form-483-frequently-asked-questions
  8. FDA — Exemptions under the Drug Supply Chain Security Act. https://www.fda.gov/drugs/drug-supply-chain-security-act-dscsa/exemptions-under-drug-supply-chain-security-act
  9. FDA — Dosing errors associated with compounded injectable semaglutide. https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-patients-dosing-errors-associated-compounded
  10. FDA — Concerns with unapproved GLP-1 drugs used for weight loss. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
  11. Eli Lilly — LillyDirect patient FAQs. https://www.lilly.com/lillydirect/faq
  12. Novo Nordisk — NovoCare delivery programme terms and conditions. https://www.novocare.com/eligibility/delivery.html
  13. HHS — Business associates guidance and FAQs. https://www.hhs.gov/hipaa/for-professionals/privacy/guidance/business-associates/index.html
  14. FDA — What telehealth companies should know when promoting compounded drugs. https://www.fda.gov/drugs/human-drug-compounding/fda-telehealth-companies-what-know-when-promoting-compounded-drugs

Sources cited on this page

  1. fda.gov · Source 1 ↗https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
  2. fda.gov · Source 2 ↗https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list
  3. fda.gov · Source 3 ↗https://www.fda.gov/drugs/human-drug-compounding/fdc-act-provisions-apply-human-drug-compounding
  4. pharmacy.ca.gov · Source 4 ↗https://www.pharmacy.ca.gov/about/verify_lic
  5. pharmacy.ca.gov · Source 5 ↗https://www.pharmacy.ca.gov/forms/nrp_comp_app_pkt.pdf
  6. fda.gov · Source 6 ↗https://www.fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities
  7. fda.gov · Source 7 ↗https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/inspection-references/fda-form-483-frequently-asked-questions
  8. fda.gov · Source 8 ↗https://www.fda.gov/drugs/drug-supply-chain-security-act-dscsa/exemptions-under-drug-supply-chain-security-act
  9. fda.gov · Source 9 ↗https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-patients-dosing-errors-associated-compounded
  10. fda.gov · Source 10 ↗https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
  11. lilly.com · Source 11 ↗https://www.lilly.com/lillydirect/faq
  12. novocare.com · Source 12 ↗https://www.novocare.com/eligibility/delivery.html
  13. hhs.gov · Source 13 ↗https://www.hhs.gov/hipaa/for-professionals/privacy/guidance/business-associates/index.html
  14. fda.gov · Source 14 ↗https://www.fda.gov/drugs/human-drug-compounding/fda-telehealth-companies-what-know-when-promoting-compounded-drugs
Section sources →